RTTNews BiotechCodex · 实盘不做把握 8/10
北京时间·🕒 发布 21:29:16时区推断·⟳ 抓取 21:30:32·⚡ 决策 07-30 21:31:52 +1m20s·89.1 天前
Nuwellis 的 Aquadex 儿科回顾性研究获期刊接收，盘前股价暴涨
本次只是 Frontiers in Pediatrics 接收单中心回顾性可行性研究，不是 FDA 批准、商业订单、报销突破或销售指引上修。
📄 原文RTTNews Biotech↗ 原文
Nuwellis Study Acceptance Highlights Aquadex In Pediatric Care, Stock Rockets In Pre-Market
Nuwellis, Inc. (NUWE) announced that Frontiers in Pediatrics has accepted publication of a new single-center retrospect…
不做 Nuwellis（NUWE.US）
不做：期刊接收的单中心回顾性可行性研究不是商业化或监管硬催化，且盘前已暴涨约175%，追多没有正期望。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-30 · 扩散 medium · price-in 风险 high ↗
关键理由
- 本次只是 Frontiers in Pediatrics 接收单中心回顾性可行性研究，不是 FDA 批准、商业订单、报销突破或销售指引上修。
- 研究样本仅 46 名儿童、52 个疗程，正文也明确其为 feasibility report 而非优效性证明，难以直接量化为短期收入增量。
- NUWE.US 已在盘前从前收 1.89 美元涨至约 5.17 美元、涨幅约 175%，弱基本面催化已被极端交易化。
主要风险
- 微盘生物医疗设备股叠加 1-for-35 反向拆股后波动和流动性风险高，盘前暴涨后容易高开低走。
- 若后续出现真实商业订单、报销覆盖或指南级采纳，需要按新催化重新评估。
原文全文
展开原文 · 2,313 字
Nuwellis, Inc. (NUWE) announced that Frontiers in Pediatrics has accepted publication of a new single-center retrospective study evaluating Epoprostenol as an alternative anticoagulant for its Aquadex ultrafiltration therapy in critically ill children.
Epoprostenol is a short-acting drug that prevents platelet clumping, used as the sole anticoagulant during Aquadex treatment in pediatric intensive care.
Aquadex SmartFlow is the company's proprietary ultrafiltration system designed to safely remove excess fluid in patients with fluid overload. Compact and precise, it allows clinicians to tailor fluid removal rates to individual needs, including children with heart failure or critical illness.
The findings showed that the approach-maintained circuit performance, did not increase the need for blood-pressure support, and was not associated with bleeding events. Researchers reviewed 46 children across 52 treatment courses at UPMC Children's Hospital of Pittsburgh between September 2022 and September 2025. Filters lasted a median of two days, platelet counts remained stable or improved, and no bleeding was attributed to the drug.
Nuwellis CEO Mike McCormick said the acceptance represents another milestone in building clinical evidence for Aquadex therapy in pediatric critical care, adding that high-quality data is essential to expanding physician confidence. Senior author Dana Y. Fuhrman, DO, MS, noted that Epoprostenol could provide physicians "another tool at the bedside" without adding bleeding risk or requiring intensive monitoring.The study is framed as a feasibility report rather than proof of superiority, but it adds to the growing body of evidence supporting Aquadex in complex pediatric cases.
The company recently implemented a 1-for-35 reverse stock split on July 26, 2026.
NUWE closed Wednesday's trading at $1.89, down 2.07%. In pre-market trading the stock is at $5.17, up 175.49%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 30, 2026 04:24 ET The August 2026 FDA calendar features several important PDUFA decisions that could influence the biotech sector, healthcare innovation, and investor sentiment. In this video, we break down five major FDA decisions expected in August 2026, including the therapies, companies, and diseases under review:
Epoprostenol is a short-acting drug that prevents platelet clumping, used as the sole anticoagulant during Aquadex treatment in pediatric intensive care.
Aquadex SmartFlow is the company's proprietary ultrafiltration system designed to safely remove excess fluid in patients with fluid overload. Compact and precise, it allows clinicians to tailor fluid removal rates to individual needs, including children with heart failure or critical illness.
The findings showed that the approach-maintained circuit performance, did not increase the need for blood-pressure support, and was not associated with bleeding events. Researchers reviewed 46 children across 52 treatment courses at UPMC Children's Hospital of Pittsburgh between September 2022 and September 2025. Filters lasted a median of two days, platelet counts remained stable or improved, and no bleeding was attributed to the drug.
Nuwellis CEO Mike McCormick said the acceptance represents another milestone in building clinical evidence for Aquadex therapy in pediatric critical care, adding that high-quality data is essential to expanding physician confidence. Senior author Dana Y. Fuhrman, DO, MS, noted that Epoprostenol could provide physicians "another tool at the bedside" without adding bleeding risk or requiring intensive monitoring.The study is framed as a feasibility report rather than proof of superiority, but it adds to the growing body of evidence supporting Aquadex in complex pediatric cases.
The company recently implemented a 1-for-35 reverse stock split on July 26, 2026.
NUWE closed Wednesday's trading at $1.89, down 2.07%. In pre-market trading the stock is at $5.17, up 175.49%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 30, 2026 04:24 ET The August 2026 FDA calendar features several important PDUFA decisions that could influence the biotech sector, healthcare innovation, and investor sentiment. In this video, we break down five major FDA decisions expected in August 2026, including the therapies, companies, and diseases under review:
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。